Developer docs
API playgroundTry for free, no card

Search company profiles

TMC Pharma

Full company profile

uuid0002lc3

Namestring
TMC Pharma
Legal namestring
TMC Pharma Services Ltd
Websiteurl
tmcpharma.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

TMC Pharma Services Ltd is a UK-headquartered pharmaceutical development organisation providing integrated drug development services to small and mid-sized biotech and pharmaceutical companies. Founded in 2000 and headquartered in Hartley Wintney with operating subsidiaries in Ireland (TMC Pharma EU Ltd) and a North American presence in Gaithersburg, Maryland, the company reorganised in November 2025 into three service lines: TMC Consulting (regulatory affairs, clinical development, pharmacovigilance, medical services and quality management consultancy), TMC Clinical (early-phase clinical research organisation services focused on rare disease, complex oncology and advanced therapeutic modalities), and TMC Commercial (EU/UK drug commercialisation, market access and Marketing Authorisation Holder services).

TMC does not develop proprietary technology platforms; its offering is an expert-led professional services model delivered through a network of senior specialists and associates who integrate into client teams. The firm leverages AI/ML tools for pharmacovigilance signal detection, natural language processing of unstructured clinical narratives, and multimodal data analysis to support site targeting and cohort estimation for clinical trials, but these capabilities are positioned as delivery accelerators rather than standalone products. The company is GDPR-compliant across UK and EU entities and holds no patents on its service methodology.

TMC operates a sales-led go-to-market targeting pharmaceutical and biotech sponsors through direct enterprise engagement, conference participation (BIO-Europe, BIO International), thought leadership content and referrals. Pricing is bespoke and project-based, typically structured as multi-year contracts. The firm is privately held, having received an £18 million growth investment from LDC (the private equity arm of Lloyds Banking Group) in August 2022 to fund international expansion, and is led by CEO Simon Estcourt (appointed May 2024) and CFO Joe Lopez (appointed June 2024). In 2026 TMC was awarded Rare Disease CRO of the Year by Global Health & Pharma and joined OTXL's Orphan ClinDevNet network.

Short descriptiontext

TMC Pharma is a UK-headquartered pharmaceutical development organisation providing integrated consulting, early-phase clinical research, and EU/UK drug commercialisation services to small and mid-sized biotech and pharma companies, with specialist focus on rare disease, complex oncology and advanced therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHartley Wintney, United Kingdom
HQ citystring
Hartley Wintney
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical services, clinical research organization, drug development consulting, regulatory affairs services, pharmacovigilance services
Industry2 codes
PRIMARYTHAKACAD
Enterprise/Global Account Corporate TMCs
SECONDARYTHAKACAA
Full-Service Corporate TMCs (End-to-End Managed Travel)
NAICS code3 codes
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
  • Scientific Research and Development Services5417
  • Management Consulting Services54161
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Services / Contract Research Organization (CRO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharma Consulting Services
TypeProfessional Services
Description

Expert-led strategic and operational pharma consultancy spanning drug regulatory affairs, clinical development, pharmacovigilance, medical services and quality management. Services are delivered by experienced specialists who integrate flexibly with client teams.

tmcpharma.com
2Early-Phase Clinical Development
TypeProfessional Services
Description

Clinical research organisation services specialising in rare disease, complex oncology and advanced therapeutic modalities. Provides complete clinical trial execution from site feasibility through to medical monitoring and regulatory reporting.

tmcpharma.com
3Drug Commercialisation Services
TypeProfessional Services
Description

Full-service drug commercialisation in EU and UK including marketing authorisation holder (MAH) capabilities. Provides regulatory compliance, market access strategy, and commercial launch support.

tmcpharma.com
4Three Specialist Service Lines
TypeProfessional Services
Description

TMC reorganised into three dedicated service lines: TMC Consulting, TMC Clinical, and TMC Commercial, providing end-to-end support from early-stage development to market access and drug commercialisation.

biospace.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom professional services engagements
ModelOtherBilling cadenceMulti-year contract
Notes

Services are priced on a project-by-project basis depending on scope, duration, and specific requirements. No public pricing tiers are available as engagements are tailored to each biotech or pharma company's drug development needs.

tmcpharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1TMC Consulting
Description

Expert-led strategic and operational pharma consultancy services spanning drug regulatory affairs, clinical development, pharmacovigilance, medical services and quality management

biospace.com
+2 more records
Core offering1 text field

TMC Pharma is a global pharmaceutical services company delivering integrated drug development solutions across the full product lifecycle, organized into three service lines: TMC Consulting (regulatory affairs, clinical development, pharmacovigilance, medical services, quality management consultancy), TMC Clinical (early-phase clinical trials for rare disease, complex oncology and advanced therapeutics), and TMC Commercial (EU/UK drug commercialisation and Marketing Authorisation Holder services). Services are delivered by experienced senior specialists and freelance associates who integrate flexibly with client teams.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successful CTA approval across four EU countries
+1 more record
Product overview1 text field

TMC is a global pharma services company delivering integrated drug development solutions across the full product lifecycle through three specialist service lines. TMC Consulting provides regulatory affairs, clinical development, pharmacovigilance, medical services and quality management consultancy. TMC Clinical specialises in early-phase clinical trials for rare disease, complex oncology and advanced therapeutic modalities. TMC Commercial offers EU/UK drug commercialisation services including market access support and Marketing Authorisation Holder capabilities. Together, these services enable end-to-end support from early-stage clinical development to market entry and post-approval compliance.

Product and service3 records
1TMC Consulting
CategoryPharma Consulting Services
Description

Expert-led strategic and operational pharma consultancy services spanning drug regulatory affairs, clinical development, pharmacovigilance, medical services and quality management. Experienced specialists integrate key roles into client teams to help reach drug development milestones compliantly, quickly and cost-effectively. Targeted at biotech and pharma companies needing outsourced expertise.

2TMC Clinical
CategoryClinical Research Organization (CRO) Services
Description

Early-phase clinical development solutions for rare disease, complex oncology and advanced therapeutic modalities. Combines the responsiveness of a specialist pharma services company with the expertise of a clinical research organisation (CRO) to accelerate drug development timelines, reduce risk and move toward global new drug approvals.

3TMC Commercial
CategoryDrug Commercialisation Services
Description

Flexible, full-service drug commercialisation services in the EU and UK, from preparing for submission to post-authorisation. Provides specialist expertise to act as Marketing Authorisation Holder (MAH), either as a temporary bridge or long-term solution. Enables biotech and pharma companies to build their own European commercial presence without out-licensing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

TMC joined OTXL's Orphan ClinDevNet network, a development network designed to overcome barriers that cause ultra-rare disease therapies to stall. TMC contributes UK and European market access, commercialisation, regulatory, and consultative CRO capabilities. The partnership adds targeted capabilities for clinical programs requiring earlier integration of clinical strategy, regulatory planning, and market access considerations in the UK and Europe.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

OPIS joined Orphan ClinDevNet alongside TMC, adding global clinical development and trial execution expertise across Europe, Asia, and the Americas with extensive rare disease research experience.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Uniphar joined Orphan ClinDevNet alongside TMC, adding expanded access program capabilities to the network with experience in pharmaceutical distribution, healthcare logistics, and related support services.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

SK pharmteco joined Orphan ClinDevNet alongside TMC, adding U.S.-based manufacturing capabilities for viral vector platforms as a global contract development and manufacturing organisation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Premier Research is a mid-market CRO focused on rare disease, oncology, and pediatric indications. Comparable to TMC in therapeutic specialization and biotech client base, with overlapping regulatory and clinical development capabilities.

TypeDirect peer
Description

Ergomed is a UK-based CRO specializing in rare disease and oncology, with a similar associate-based service model. Highly comparable to TMC on therapeutic focus, geographic footprint, and target customer (small/mid-sized biotech), making it the closest direct competitor.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-market CRO with strong rare disease, neuroscience, and cardiometabolic expertise. Comparable to TMC in scale, biotech focus, and integrated clinical-regulatory service delivery.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO and healthcare data company, offering clinical, commercial, and technology services across all therapeutic areas. Comparable as a CRO serving biotech, but operates at vastly greater scale with proprietary data assets TMC does not have.

TypeEmerging player
Description

Clinipace/dMed is a mid-size global CRO with therapeutic expertise across oncology and rare disease, serving small/mid-sized biotech. Comparable to TMC in scale, customer segment, and integrated clinical-regulatory model.

TypeDirect peer
Description

Medpace is a mid-size full-service CRO with a strong biotech and oncology focus, operating globally. Comparable to TMC on customer segment and therapeutic areas, but with substantially larger scale and US-centric operations.

TypeDirect peer
Description

Parexel is a global CRO with strong biotech and rare disease capabilities, including regulatory, clinical, and market access services. Directly comparable to TMC's integrated model, though Parexel operates at much larger scale post-Goldman Sachs and EQT ownership transitions.

TypeDirect peer
Description

Precision for Medicine is a CRO specializing in biomarker-driven trials, rare disease, and oncology, with strong precision medicine capabilities. Comparable to TMC on rare disease focus and biotech client base, with broader laboratory and translational service offerings.

9Veristat
TypeEmerging player
Description

Veristat is a US-based CRO focused on biostatistics, clinical, and regulatory services for small biotech. Comparable to TMC's consulting and clinical offerings, particularly for early-stage and niche therapy programs.

TypeDirect peer
Description

ICON is one of the largest global CROs providing clinical development, regulatory, and commercialization services to pharma and biotech. Comparable to TMC as a full-service CRO serving biotech sponsors, though at meaningfully larger scale and broader therapeutic reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TMC Pharma

Pharmaceutical Services / Contract Research Organization (CRO)tmcpharma.com

TMC Pharma is a UK-headquartered pharmaceutical development organisation providing integrated consulting, early-phase clinical research, and EU/UK drug commercialisation services to small and mid-sized biotech and pharma companies, with specialist focus on rare disease, complex oncology and advanced therapeutics.

What TMC Pharma does

TMC Pharma Services Ltd is a UK-headquartered pharmaceutical development organisation providing integrated drug development services to small and mid-sized biotech and pharmaceutical companies. Founded in 2000 and headquartered in Hartley Wintney with operating subsidiaries in Ireland (TMC Pharma EU Ltd) and a North American presence in Gaithersburg, Maryland, the company reorganised in November 2025 into three service lines: TMC Consulting (regulatory affairs, clinical development, pharmacovigilance, medical services and quality management consultancy), TMC Clinical (early-phase clinical research organisation services focused on rare disease, complex oncology and advanced therapeutic modalities), and TMC Commercial (EU/UK drug commercialisation, market access and Marketing Authorisation Holder services).

TMC does not develop proprietary technology platforms; its offering is an expert-led professional services model delivered through a network of senior specialists and associates who integrate into client teams. The firm leverages AI/ML tools for pharmacovigilance signal detection, natural language processing of unstructured clinical narratives, and multimodal data analysis to support site targeting and cohort estimation for clinical trials, but these capabilities are positioned as delivery accelerators rather than standalone products. The company is GDPR-compliant across UK and EU entities and holds no patents on its service methodology.

TMC operates a sales-led go-to-market targeting pharmaceutical and biotech sponsors through direct enterprise engagement, conference participation (BIO-Europe, BIO International), thought leadership content and referrals. Pricing is bespoke and project-based, typically structured as multi-year contracts. The firm is privately held, having received an £18 million growth investment from LDC (the private equity arm of Lloyds Banking Group) in August 2022 to fund international expansion, and is led by CEO Simon Estcourt (appointed May 2024) and CFO Joe Lopez (appointed June 2024). In 2026 TMC was awarded Rare Disease CRO of the Year by Global Health & Pharma and joined OTXL's Orphan ClinDevNet network.

TMC Pharma firmographics

Firmographics
Name
TMC Pharma
Legal name
TMC Pharma Services Ltd
Website
https://tmcpharma.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
TMC Pharma is a UK-headquartered pharmaceutical development organisation providing integrated consulting, early-phase clinical research, and EU/UK drug commercialisation services to small and mid-sized biotech and pharma companies, with specialist focus on rare disease, complex oncology and advanced therapeutics.
Ownership category
akta.pro rank

TMC Pharma industry classification

Industry
Product category
Pharmaceutical Services / Contract Research Organization (CRO)
NAICS
Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292), Scientific Research and Development Services (5417), Management Consulting Services (54161)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYTHAKACAD
Enterprise/Global Account Corporate TMCs
SECONDARYTHAKACAA
Full-Service Corporate TMCs (End-to-End Managed Travel)

Keywords

  • Pharmaceutical services
  • Clinical research organization
  • Drug development consulting
  • Regulatory affairs services
  • Pharmacovigilance services

Where TMC Pharma is headquartered

Location

Headquarters

HQ city
Hartley Wintney
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

TMC Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharma Consulting Services: Expert-led strategic and operational pharma consultancy spanning drug regulatory affairs, clinical development, pharmacovigilance, medical services and quality management. Services are delivered by experienced specialists who integrate flexibly with client teams.
  2. Early-Phase Clinical Development: Clinical research organisation services specialising in rare disease, complex oncology and advanced therapeutic modalities. Provides complete clinical trial execution from site feasibility through to medical monitoring and regulatory reporting.
  3. Drug Commercialisation Services: Full-service drug commercialisation in EU and UK including marketing authorisation holder (MAH) capabilities. Provides regulatory compliance, market access strategy, and commercial launch support.
  4. Three Specialist Service Lines: TMC reorganised into three dedicated service lines: TMC Consulting, TMC Clinical, and TMC Commercial, providing end-to-end support from early-stage development to market access and drug commercialisation.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom professional services engagements

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

TMC Pharma product offering

Product offering

Core offering

TMC Pharma is a global pharmaceutical services company delivering integrated drug development solutions across the full product lifecycle, organized into three service lines: TMC Consulting (regulatory affairs, clinical development, pharmacovigilance, medical services, quality management consultancy), TMC Clinical (early-phase clinical trials for rare disease, complex oncology and advanced therapeutics), and TMC Commercial (EU/UK drug commercialisation and Marketing Authorisation Holder services). Services are delivered by experienced senior specialists and freelance associates who integrate flexibly with client teams.

Product overview

TMC is a global pharma services company delivering integrated drug development solutions across the full product lifecycle through three specialist service lines. TMC Consulting provides regulatory affairs, clinical development, pharmacovigilance, medical services and quality management consultancy. TMC Clinical specialises in early-phase clinical trials for rare disease, complex oncology and advanced therapeutic modalities. TMC Commercial offers EU/UK drug commercialisation services including market access support and Marketing Authorisation Holder capabilities. Together, these services enable end-to-end support from early-stage clinical development to market entry and post-approval compliance.

Differentiator

Problem solved

Functional benefit

Brands

  • TMC Consulting: Expert-led strategic and operational pharma consultancy services spanning drug regulatory affairs, clinical development, pharmacovigilance, medical services and quality management
  • TMC Clinical
  • TMC Commercial

Products and services

  • TMC Consulting Expert-led strategic and operational pharma consultancy services spanning drug regulatory affairs, clinical development, pharmacovigilance, medical services and quality management. Experienced specialists integrate key roles into client teams to help reach drug development milestones compliantly, quickly and cost-effectively. Targeted at biotech and pharma companies needing outsourced expertise.
  • TMC Clinical Early-phase clinical development solutions for rare disease, complex oncology and advanced therapeutic modalities. Combines the responsiveness of a specialist pharma services company with the expertise of a clinical research organisation (CRO) to accelerate drug development timelines, reduce risk and move toward global new drug approvals.
  • TMC Commercial Flexible, full-service drug commercialisation services in the EU and UK, from preparing for submission to post-authorisation. Provides specialist expertise to act as Marketing Authorisation Holder (MAH), either as a temporary bridge or long-term solution. Enables biotech and pharma companies to build their own European commercial presence without out-licensing.

Quantifiable outcome

  • Successful CTA approval across four EU countries
  • +1 more outcomes

Companies that use TMC Pharma

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

TMC Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

TMC Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Orphan Therapeutics Accelerator (OTXL)coreStrategic or Co-development Partner · 23 June 2026TMC joined OTXL's Orphan ClinDevNet network, a development network designed to overcome barriers that cause ultra-rare disease therapies to stall. TMC contributes UK and European market access, commercialisation, regulatory, and consultative CRO capabilities. The partnership adds targeted capabilities for clinical programs requiring earlier integration of clinical strategy, regulatory planning, and market access considerations in the UK and Europe.
  • OPISminorStrategic or Co-development Partner · 23 June 2026OPIS joined Orphan ClinDevNet alongside TMC, adding global clinical development and trial execution expertise across Europe, Asia, and the Americas with extensive rare disease research experience.
  • UnipharminorStrategic or Co-development Partner · 23 June 2026Uniphar joined Orphan ClinDevNet alongside TMC, adding expanded access program capabilities to the network with experience in pharmaceutical distribution, healthcare logistics, and related support services.
  • SK pharmtecominorStrategic or Co-development Partner · 23 June 2026SK pharmteco joined Orphan ClinDevNet alongside TMC, adding U.S.-based manufacturing capabilities for viral vector platforms as a global contract development and manufacturing organisation.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

TMC Pharma competitors and assessment

Company assessment

Direct peers

  • Premier Research: Premier Research is a mid-market CRO focused on rare disease, oncology, and pediatric indications. Comparable to TMC in therapeutic specialization and biotech client base, with overlapping regulatory and clinical development capabilities.
  • Ergomed plc: Ergomed is a UK-based CRO specializing in rare disease and oncology, with a similar associate-based service model. Highly comparable to TMC on therapeutic focus, geographic footprint, and target customer (small/mid-sized biotech), making it the closest direct competitor.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-market CRO with strong rare disease, neuroscience, and cardiometabolic expertise. Comparable to TMC in scale, biotech focus, and integrated clinical-regulatory service delivery.
  • Medpace Holdings: Medpace is a mid-size full-service CRO with a strong biotech and oncology focus, operating globally. Comparable to TMC on customer segment and therapeutic areas, but with substantially larger scale and US-centric operations.
  • Parexel International: Parexel is a global CRO with strong biotech and rare disease capabilities, including regulatory, clinical, and market access services. Directly comparable to TMC's integrated model, though Parexel operates at much larger scale post-Goldman Sachs and EQT ownership transitions.
  • Precision for Medicine: Precision for Medicine is a CRO specializing in biomarker-driven trials, rare disease, and oncology, with strong precision medicine capabilities. Comparable to TMC on rare disease focus and biotech client base, with broader laboratory and translational service offerings.
  • ICON plc: ICON is one of the largest global CROs providing clinical development, regulatory, and commercialization services to pharma and biotech. Comparable to TMC as a full-service CRO serving biotech sponsors, though at meaningfully larger scale and broader therapeutic reach.

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO and healthcare data company, offering clinical, commercial, and technology services across all therapeutic areas. Comparable as a CRO serving biotech, but operates at vastly greater scale with proprietary data assets TMC does not have.

Emerging players

  • Clinipace Worldwide (now dMed): Clinipace/dMed is a mid-size global CRO with therapeutic expertise across oncology and rare disease, serving small/mid-sized biotech. Comparable to TMC in scale, customer segment, and integrated clinical-regulatory model.
  • Veristat: Veristat is a US-based CRO focused on biostatistics, clinical, and regulatory services for small biotech. Comparable to TMC's consulting and clinical offerings, particularly for early-stage and niche therapy programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

TMC Pharma social profiles

Digital presence

TMC Pharma compliance and trust

Trust signal

Compliance1 record

TMC Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TMC Pharma leadership team

Management profile

Number of profiles

Profiles5 records

TMC Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TMC Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TMC Pharma

What does TMC Pharma do?

TMC Pharma is a global pharmaceutical services company delivering integrated drug development solutions across the full product lifecycle, organized into three service lines: TMC Consulting (regulatory affairs, clinical development, pharmacovigilance, medical services, quality management consultancy), TMC Clinical (early-phase clinical trials for rare disease, complex oncology and advanced therapeutics), and TMC Commercial (EU/UK drug commercialisation and Marketing Authorisation Holder services). Services are delivered by experienced senior specialists and freelance associates who integrate flexibly with client teams.

Is TMC Pharma a public or private company?

TMC Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was TMC Pharma founded?

TMC Pharma was founded in 2000. It employs 51 to 100 people.

Where is TMC Pharma based?

TMC Pharma is headquartered in Hartley Wintney, United Kingdom, in the Europe region.

How does TMC Pharma make money?

Four revenue lines are on record. Pharma Consulting Services are the primary driver. The others are early-Phase Clinical Development, drug Commercialisation Services and three Specialist Service Lines.

Who are TMC Pharma's main competitors?

Direct peers on record are Premier Research, Ergomed plc, Worldwide Clinical Trials, Medpace Holdings, Parexel International, Precision for Medicine and ICON plc. IQVIA is listed as a broad incumbent. Emerging players are Clinipace Worldwide (now dMed) and Veristat.

Does TMC Pharma have an API?

No public API is recorded for TMC Pharma.

What industry is TMC Pharma in?

TMC Pharma's product category is Pharmaceutical Services / Contract Research Organization (CRO). Its primary akta.pro industry code is THAKACAD, Enterprise/Global Account Corporate TMCs, with a secondary code of THAKACAA, Full-Service Corporate TMCs (End-to-End Managed Travel). Its NAICS code is 524292 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaPharma consultancy bought in pre-pack deal by global network - saves 45 jobsSpecialist pharmaceutical consultancy tranScrip has been acquired by global network TMC Pharma Services in a pre-pack deal following its administration earlier this month. The acquisition secures 45 jobs and integrates tranScrip's drug development capabilities into TMC's existing operations across the UK, US, and Ireland.AijournOrphan Therapeutics Accelerator Expands its Network to Extend Development and Access Pathways for Ultra-Rare Disease TherapiesOrphan Therapeutics Accelerator (OTXL) announced the expansion of its development network, Orphan ClinDevNet, through the addition of four strategic partners: OPIS, Uniphar, SK pharmteco, and TMC Pharma. The new partners add targeted capabilities across clinical trial execution, expanded access programs, U.S.-based viral vector manufacturing, and UK/European regulatory and market access expertise. This expansion aims to help overcome barriers that cause ultra-rare disease therapies to stall, by providing a decentralized, outsourced infrastructure for development and commercialization.PR NewswireOrphan Therapeutics Accelerator Expands its Network to Extend Development and Access Pathways for Ultra-Rare Disease TherapiesOrphan Therapeutics Accelerator (OTXL) announced the expansion of its development network, Orphan ClinDevNet, through the addition of four strategic partners: OPIS, Uniphar, SK pharmteco, and TMC Pharma. The expansion adds capabilities across clinical trial execution, expanded access programs, U.S.-based viral vector manufacturing, and UK/European market access and regulatory strategy for ultra-rare disease therapies. OTXL works to advance shelved rare disease treatments that stall due to small patient populations and prohibitive development costs and risks that make traditional biopharma development commercially unviable.LDCLDC invests £18m in TMC Pharma ServicesPrivate equity firm LDC has made an £18m minority investment in TMC Pharma Services, a global pharmaceutical development organization specializing in rare diseases and oncology. The funding is intended to support TMC's expansion into US and Asian markets, alongside plans to double its full-time workforce over the next five years. Both parties' representatives will join the board to oversee this strategic growth phase.